Tech Company Inital Public Offerings
Trius Therapeutics IPO
On 8/3/2010, Trius Therapeutics completed its IPO
Transaction Overview
Company Name
Announced On
8/3/2010
Transaction Type
IPO
Amount
$50,000,000
Proceeds Purpose
Proceeds purposes are on file in the company statements with the SEC.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
6310 Nancy Ridge Drive 105
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Trius Therapeutics is discovering and developing innovative antibacterial drugs for thetreatment of life-threatening infections. The company's lead product candidate, TR-701 isa novel oral and IV oxazolidinone antibiotic with potent activity against Gram positivebacterial pathogens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Stein
Chief Financial Officer
John Schmid
Chief Medical Officer
Philippe Prokocimer
Chief Scientific Officer
John Finn
VP - Bus. Development
Neil Abdollahian
VP - Regulatory Affairs
Karen Potts
Browse more venture capital transactions:
Prev: 8/3/2010: SilverRail Technologies venture capital transaction
Next: 8/3/2010: Provade venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs